← Incyte overview

Incyte vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Incyte Corporation (INCY)

Q3 2026
▲3

Incyte's Q2 Beat and Raised Guidance Drive Stock to 52-Week High

  • Q2 Earnings Beat and Raised 2026 Guidance Incyte reported Q2 earnings of $3.09 per share, beating estimates, with revenue up 38% to $1.67 billion. The company raised full-year product sales guidance to $5.13-$5.26 billion, driven by strong Jakafi and Opzelura sales. This directly boosts investor confidence and pushes INCY shares higher.

    This is the main new event that drove the stock up 9.3% and to a 52-week high.

  • Latarcibart Shows Strong Phase 1/2 Data and Acquisition of Vega Therapeutics Incyte reported an 81% median bleed reduction with latarcibart in von Willebrand disease and acquired Vega Therapeutics, gaining full rights. This strengthens the hematology pipeline and reduces reliance on Jakafi, supporting future growth and lifting the stock.

    New clinical data and a strategic acquisition that expands the pipeline and diversifies revenue.

  • Halozyme Enhanze Deal for INCA033989 Incyte signed a global license with Halozyme to use Enhanze delivery technology for its phase 3 candidate INCA033989, with options for two more assets. This could improve dosing and commercial potential, adding upside to the pipeline and supporting the stock.

    A new collaboration that enhances a late-stage asset and shows pipeline progress.

July 2026
▲3

Incyte's Q2 Beat and Raised Guidance Drive Stock to 52-Week High

  • Q2 Earnings Beat and Raised 2026 Guidance Incyte reported Q2 earnings of $3.09 per share, beating estimates, with revenue up 38% to $1.67 billion. The company raised full-year product sales guidance to $5.13-$5.26 billion, driven by strong Jakafi and Opzelura sales. This directly boosts investor confidence and pushes INCY shares higher.

    This is the main new event that drove the stock up 9.3% and to a 52-week high.

  • Latarcibart Shows Strong Phase 1/2 Data and Acquisition of Vega Therapeutics Incyte reported an 81% median bleed reduction with latarcibart in von Willebrand disease and acquired Vega Therapeutics, gaining full rights. This strengthens the hematology pipeline and reduces reliance on Jakafi, supporting future growth and lifting the stock.

    New clinical data and a strategic acquisition that expands the pipeline and diversifies revenue.

  • Halozyme Enhanze Deal for INCA033989 Incyte signed a global license with Halozyme to use Enhanze delivery technology for its phase 3 candidate INCA033989, with options for two more assets. This could improve dosing and commercial potential, adding upside to the pipeline and supporting the stock.

    A new collaboration that enhances a late-stage asset and shows pipeline progress.

Latest
▲3

Incyte's Q2 Beat and Raised Guidance Drive Stock to 52-Week High

  • Q2 Earnings Beat and Raised 2026 Guidance Incyte reported Q2 earnings of $3.09 per share, beating estimates, with revenue up 38% to $1.67 billion. The company raised full-year product sales guidance to $5.13-$5.26 billion, driven by strong Jakafi and Opzelura sales. This directly boosts investor confidence and pushes INCY shares higher.

    This is the main new event that drove the stock up 9.3% and to a 52-week high.

  • Latarcibart Shows Strong Phase 1/2 Data and Acquisition of Vega Therapeutics Incyte reported an 81% median bleed reduction with latarcibart in von Willebrand disease and acquired Vega Therapeutics, gaining full rights. This strengthens the hematology pipeline and reduces reliance on Jakafi, supporting future growth and lifting the stock.

    New clinical data and a strategic acquisition that expands the pipeline and diversifies revenue.

  • Halozyme Enhanze Deal for INCA033989 Incyte signed a global license with Halozyme to use Enhanze delivery technology for its phase 3 candidate INCA033989, with options for two more assets. This could improve dosing and commercial potential, adding upside to the pipeline and supporting the stock.

    A new collaboration that enhances a late-stage asset and shows pipeline progress.

Q2 2026
▲4

Incyte Advances New Drugs and Regulatory Wins, Lifting Outlook

  • Zilurgisertib Phase II Success and FDA Priority Review Incyte's drug zilurgisertib showed strong Phase II results in a rare bone disease, and the FDA accepted its application with Priority Review, setting a decision date for September 2026. This raises the chance of a new approval and future revenue, pushing INCY shares up.

    This is a new clinical and regulatory milestone that directly boosts INCY's pipeline value.

  • Minjuvi Approved in Japan for DLBCL Japan's health ministry approved Incyte's Minjuvi for a type of lymphoma, expanding the drug's market. This adds a new source of sales in Japan, which is positive for INCY's revenue growth.

    A new geographic approval for an existing drug increases INCY's addressable market.

  • Opzelura Gets Positive EU Opinion for Atopic Dermatitis The European Medicines Agency's committee recommended approval of Opzelura cream for moderate atopic dermatitis in adults. If approved, it would be the first steroid-free topical JAK inhibitor in the EU, opening a large new market and lifting INCY's growth prospects.

    This is a new regulatory step that could significantly expand Opzelura's sales in Europe.

  • CMS Litigation Resolution Brings One-Time Benefit Incyte settled a dispute with CMS over Medicaid rebate rules, resulting in a one-time $246 million benefit in Q2 2026. This boosts near-term earnings and removes a legal overhang, supporting the stock price.

    A new legal settlement that provides a financial boost and reduces uncertainty.

June 2026
▲4

Incyte Advances New Drugs and Regulatory Wins, Lifting Outlook

  • Zilurgisertib Phase II Success and FDA Priority Review Incyte's drug zilurgisertib showed strong Phase II results in a rare bone disease, and the FDA accepted its application with Priority Review, setting a decision date for September 2026. This raises the chance of a new approval and future revenue, pushing INCY shares up.

    This is a new clinical and regulatory milestone that directly boosts INCY's pipeline value.

  • Minjuvi Approved in Japan for DLBCL Japan's health ministry approved Incyte's Minjuvi for a type of lymphoma, expanding the drug's market. This adds a new source of sales in Japan, which is positive for INCY's revenue growth.

    A new geographic approval for an existing drug increases INCY's addressable market.

  • Opzelura Gets Positive EU Opinion for Atopic Dermatitis The European Medicines Agency's committee recommended approval of Opzelura cream for moderate atopic dermatitis in adults. If approved, it would be the first steroid-free topical JAK inhibitor in the EU, opening a large new market and lifting INCY's growth prospects.

    This is a new regulatory step that could significantly expand Opzelura's sales in Europe.

  • CMS Litigation Resolution Brings One-Time Benefit Incyte settled a dispute with CMS over Medicaid rebate rules, resulting in a one-time $246 million benefit in Q2 2026. This boosts near-term earnings and removes a legal overhang, supporting the stock price.

    A new legal settlement that provides a financial boost and reduces uncertainty.

▲4

Incyte Advances New Drugs and Regulatory Wins, Lifting Outlook

  • Zilurgisertib Phase II Success and FDA Priority Review Incyte's drug zilurgisertib showed strong Phase II results in a rare bone disease, and the FDA accepted its application with Priority Review, setting a decision date for September 2026. This raises the chance of a new approval and future revenue, pushing INCY shares up.

    This is a new clinical and regulatory milestone that directly boosts INCY's pipeline value.

  • Minjuvi Approved in Japan for DLBCL Japan's health ministry approved Incyte's Minjuvi for a type of lymphoma, expanding the drug's market. This adds a new source of sales in Japan, which is positive for INCY's revenue growth.

    A new geographic approval for an existing drug increases INCY's addressable market.

  • Opzelura Gets Positive EU Opinion for Atopic Dermatitis The European Medicines Agency's committee recommended approval of Opzelura cream for moderate atopic dermatitis in adults. If approved, it would be the first steroid-free topical JAK inhibitor in the EU, opening a large new market and lifting INCY's growth prospects.

    This is a new regulatory step that could significantly expand Opzelura's sales in Europe.

  • CMS Litigation Resolution Brings One-Time Benefit Incyte settled a dispute with CMS over Medicaid rebate rules, resulting in a one-time $246 million benefit in Q2 2026. This boosts near-term earnings and removes a legal overhang, supporting the stock price.

    A new legal settlement that provides a financial boost and reduces uncertainty.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 2026
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 2026
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.